Clinical Trial Update: A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1) [Phase 1]

View source ↗

Summary

A multinational Phase 1 trial evaluating the oral EGFR inhibitor DZD6008 in patients with advanced EGFR-mutant Non-Small Cell Lung Cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DZD6008

Snippet

Sponsor: Dizal Pharmaceuticals | Conditions: Non Small Cell Lung Cancer | Phase 1 | Status: RECRUITING